1
|
Cardoso MJ, Poortmans P, Senkus E, Gentilini OD, Houssami N. Breast cancer highlights from 2023: Knowledge to guide practice and future research. Breast 2024; 74:103674. [PMID: 38340683 PMCID: PMC10869942 DOI: 10.1016/j.breast.2024.103674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Revised: 12/31/2023] [Accepted: 01/18/2024] [Indexed: 02/12/2024] Open
Abstract
This narrative work highlights a selection of published work from 2023 with potential implications for breast cancer practice. We feature publications that have provided new knowledge immediately relevant to patient care or for future research. We also highlight guidelines that have reported evidence-based or consensus recommendations to support practice and evaluation in breast cancer diagnosis and treatment. The scope of selected highlights represents various domains and disciplines in cancer control, from prevention to treatment of early and advanced breast cancer.
Collapse
Affiliation(s)
- Maria-Joao Cardoso
- Champalimaud Foundation Breast Unit, Lisbon, Portugal; University of Lisbon, Faculty of Medicine, Lisbon, Portugal.
| | - Philip Poortmans
- Department of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk-Antwerp, Belgium
| | - Elżbieta Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland
| | - Oreste D Gentilini
- Università Vita-Salute San Raffaele, Milano, Italy; IRCCS Ospedale San Raffaele, Milano, Italy
| | - Nehmat Houssami
- Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW, Australia; Wiser Healthcare, The University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
2
|
Gentilini OD, Cardoso MJ, Senkus E, Poortmans P. De-escalation of loco-regional treatments: Time to find a balance. Breast 2024; 73:103673. [PMID: 38295751 PMCID: PMC10844673 DOI: 10.1016/j.breast.2024.103673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2024] Open
Affiliation(s)
- Oreste D Gentilini
- Università Vita-Salute San Raffaele, Milano, Italy; IRCCS Ospedale San Raffaele, Milano, Italy.
| | - Maria-Joao Cardoso
- Champalimaud Foundation Breast Unit, Lisbon, Portugal; University of Lisbon, Faculty of Medicine, Lisbon, Portugal
| | - Elżbieta Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland
| | - Philip Poortmans
- Department of Radiation Oncology, Iridium Netwerk, Wilrijk, Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium
| |
Collapse
|
3
|
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024; 35:159-182. [PMID: 38101773 DOI: 10.1016/j.annonc.2023.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 11/21/2023] [Accepted: 11/28/2023] [Indexed: 12/17/2023] Open
Affiliation(s)
- S Loibl
- GBG Forschungs GmbH, Neu-Isenburg; Centre for Haematology and Oncology, Bethanien, Frankfurt, Germany
| | - F André
- Breast Cancer Unit, Medical Oncology Department, Gustave Roussy, Cancer Campus, Villejuif
| | - T Bachelot
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - C H Barrios
- Oncology Department, Latin American Cooperative Oncology Group and Oncoclínicas, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Bioclinicum, Karolinska Institutet and Breast Cancer Centre, Karolinska Comprehensive Cancer Centre and University Hospital, Stockholm, Sweden
| | - H J Burstein
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Foundation, Champalimaud Cancer Centre, Lisbon; Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - L A Carey
- Division of Medical Oncology, The University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - S Dawood
- Department of Oncology, Mediclinic City Hospital, Dubai, UAE
| | - L Del Mastro
- Medical Oncology Clinic, IRCCS Ospedale Policlinico San Martino, Genoa; Department of Internal Medicine and Medical Specialities, School of Medicine, University of Genoa, Genoa, Italy
| | - C Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Giessen and Marburg, Marburg
| | - E M Fallenberg
- Department of Diagnostic and Interventional Radiology, School of Medicine & Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - P A Francis
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - H Gamal-Eldin
- Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
| | - K Gelmon
- Department of Medical Oncology, British Columbia Cancer, Vancouver, Canada
| | - C E Geyer
- Department of Internal Medicine, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA
| | - M Gnant
- Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Oncology 2 Unit, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy
| | - S Gupta
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
| | - S B Kim
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - D Krug
- Department of Radiation Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Martin
- Hospital General Universitario Gregorio Maranon, Universidad Complutense, GEICAM, Madrid, Spain
| | - I Meattini
- Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy
| | - M Morrow
- Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
| | - W Janni
- Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany
| | - S Paluch-Shimon
- Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel
| | - A Partridge
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - P Poortmans
- Department of Radiation Oncology, Iridium Netwerk, Antwerp; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
| | - L Pusztai
- Yale Cancer Center, Yale School of Medicine, New Haven
| | - M M Regan
- Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - J Sparano
- Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
| | - T Spanic
- Europa Donna Slovenia, Ljubljana, Slovenia
| | - S Swain
- Medicine Department, Georgetown University Medical Centre and MedStar Health, Washington, USA
| | - S Tjulandin
- N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia
| | - M Toi
- Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Bunkyo-ku, Japan
| | - D Trapani
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - A Tutt
- Breast Cancer Research Division, The Institute of Cancer Research, London; Comprehensive Cancer Centre, Division of Cancer Studies, Kings College London, London, UK
| | - B Xu
- Department of Medical Oncology, National Cancer Centre/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - G Curigliano
- Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy
| | - N Harbeck
- Breast Centre, Department of Obstetrics & Gynaecology and Comprehensive Cancer Centre Munich, LMU University Hospital, Munich, Germany
| |
Collapse
|
4
|
Kaidar-Person O, Antunes M, Cardoso JS, Ciani O, Cruz H, Di Micco R, Gentilini OD, Gonçalves T, Gouveia P, Heil J, Kabata P, Lopes D, Martinho M, Martins H, Mavioso C, Mika M, Montenegro H, Oliveira HP, Pfob A, Rotmensz N, Schinköthe T, Silva G, Tarricone R, Cardoso MJ. Evaluating the ability of an artificial-intelligence cloud-based platform designed to provide information prior to locoregional therapy for breast cancer in improving patient's satisfaction with therapy: The CINDERELLA trial. PLoS One 2023; 18:e0289365. [PMID: 37535564 PMCID: PMC10399739 DOI: 10.1371/journal.pone.0289365] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 07/14/2023] [Indexed: 08/05/2023] Open
Abstract
BACKGROUND Breast cancer therapy improved significantly, allowing for different surgical approaches for the same disease stage, therefore offering patients different aesthetic outcomes with similar locoregional control. The purpose of the CINDERELLA trial is to evaluate an artificial-intelligence (AI) cloud-based platform (CINDERELLA platform) vs the standard approach for patient education prior to therapy. METHODS A prospective randomized international multicentre trial comparing two methods for patient education prior to therapy. After institutional ethics approval and a written informed consent, patients planned for locoregional treatment will be randomized to the intervention (CINDERELLA platform) or controls. The patients in the intervention arm will use the newly designed web-application (CINDERELLA platform, CINDERELLA APProach) to access the information related to surgery and/or radiotherapy. Using an AI system, the platform will provide the patient with a picture of her own aesthetic outcome resulting from the surgical procedure she chooses, and an objective evaluation of this aesthetic outcome (e.g., good/fair). The control group will have access to the standard approach. The primary objectives of the trial will be i) to examine the differences between the treatment arms with regards to patients' pre-treatment expectations and the final aesthetic outcomes and ii) in the experimental arm only, the agreement of the pre-treatment AI-evaluation (output) and patient's post-therapy self-evaluation. DISCUSSION The project aims to develop an easy-to-use cost-effective AI-powered tool that improves shared decision-making processes. We assume that the CINDERELLA APProach will lead to higher satisfaction, better psychosocial status, and wellbeing of breast cancer patients, and reduce the need for additional surgeries to improve aesthetic outcome.
Collapse
Affiliation(s)
- Orit Kaidar-Person
- Breast Cancer Radiation Therapy Unit, Sheba Medical Center, Ramat Gan, Israel
- School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Marilia Antunes
- Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
- Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - Jaime S Cardoso
- Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi University, Milan, Italy
- Champalimaud Foundation, Breast Unit, Lisbon, Portugal
| | - Oriana Ciani
- Institute for Systems and Computer Engineering, Technology and Science (INESC TEC), Porto, Portugal
| | - Helena Cruz
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
| | - Rosa Di Micco
- Breast Surgery Unit, San Raffaele University and Research Hospital, Milano, Italy
| | - Oreste D Gentilini
- Breast Surgery Unit, San Raffaele University and Research Hospital, Milano, Italy
| | - Tiago Gonçalves
- Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi University, Milan, Italy
- Champalimaud Foundation, Breast Unit, Lisbon, Portugal
| | - Pedro Gouveia
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
- Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
| | - Jörg Heil
- Instituto Universitario de Lisboa (ISCTE), Lisboa, Portugal
| | | | - Daniela Lopes
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
| | - Marta Martinho
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
| | - Henrique Martins
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
- Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa (CEAUL), Lisboa, Portugal
| | - Carlos Mavioso
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
| | - Martin Mika
- Department of Surgical Oncology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - Helena Montenegro
- Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi University, Milan, Italy
- Champalimaud Foundation, Breast Unit, Lisbon, Portugal
| | - Helder P Oliveira
- Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi University, Milan, Italy
- Department of Obstetrics & Gynecology, Heidelberg University Hospital, Heidelberg, Germany
| | - André Pfob
- Instituto Universitario de Lisboa (ISCTE), Lisboa, Portugal
| | - Nicole Rotmensz
- Breast Surgery Unit, San Raffaele University and Research Hospital, Milano, Italy
| | - Timo Schinköthe
- Department of Surgical Oncology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - Giovani Silva
- Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
- Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - Rosana Tarricone
- Institute for Systems and Computer Engineering, Technology and Science (INESC TEC), Porto, Portugal
| | - Maria-Joao Cardoso
- Faculty of Engineering, University of Porto (FEUP), Porto, Portugal
- Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
| |
Collapse
|
5
|
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34:33-47. [PMID: 36307055 DOI: 10.1016/j.annonc.2022.10.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 10/05/2022] [Accepted: 10/06/2022] [Indexed: 02/03/2023] Open
Affiliation(s)
- C Sessa
- Medical Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
| | - J Balmaña
- Medical Oncology Hospital Vall d'Hebron and Hereditary Cancer Genetics Group, Vall d'Hebron Institut of Oncology, Barcelona, Spain
| | - S L Bober
- Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute/Harvard Medical School, Boston, USA
| | - M J Cardoso
- Champalimaud Foundation, Breast Unit and Faculdade de Medicina, Lisbon, Portugal
| | - N Colombo
- Department of Gynecologic Oncology, Istituto Europeo di Oncologia e IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
| | - G Curigliano
- Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy
| | - S M Domchek
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - D G Evans
- Manchester Centre for Genomic Medicine, Division of Evolution Infection and Genomic Sciences, University of Manchester, MAHSC, Manchester, UK; Manchester Centre for Genomic Medicine, MAHSC, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - D Fischerova
- Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - N Harbeck
- Breast Center, Department of Obstetrics & Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany
| | - C Kuhl
- Department of Diagnostic and Interventional Radiology, University Hospital Aachen, University Hospital Aachen (UKA), RWTH Aachen, Germany
| | - B Lemley
- KIU - Patient Organisation for Women with Gynaecological Cancer, Copenhagen, Denmark; Clinical Trials Project, ESGO ENGAGe, Prague, Czech Republic
| | - E Levy-Lahad
- Medical Genetics Institute, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - M Lambertini
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - J A Ledermann
- Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK
| | - S Loibl
- GBG Forschungs GmbH, Neu-Isenburg, Germany
| | - K-A Phillips
- Department of Medical Oncology, Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
| | - S Paluch-Shimon
- Sharett Institute of Oncology Department, Hadassah University Hospital & Faculty of Medicine Hebrew University, Jerusalem, Israel
| |
Collapse
|
6
|
Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, Cardoso MJ, Curigliano G, Gelmon KA, Gentilini O, Harbeck N, Kaufman B, Kim SB, Liu Q, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Sirohi B, Spanic T, Sulosaari V, Peccatori F, Pagani O. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol 2022; 33:1097-1118. [PMID: 35934170 DOI: 10.1016/j.annonc.2022.07.007] [Citation(s) in RCA: 40] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 07/14/2022] [Accepted: 07/17/2022] [Indexed: 12/31/2022] Open
Abstract
We dedicate this manuscript in memory of a dear friend and colleague Bella Kaufman. The fifth International Consensus Symposium for Breast Cancer in Young Women (BCY5) took place virtually in October 2020, organized by the European School of Oncology (ESO) and the European Society of Medical Oncology (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY4 with incorporation of new evidence to inform the guidelines. Areas of research priorities as well as specificities in different geographic and minority populations were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA).
Collapse
Affiliation(s)
- S Paluch-Shimon
- Hadassah University Hospital & Faculty of Medicine, Hebrew University, Jerusalem, Israel.
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal
| | | | - O Abulkhair
- King Abdulaziz Medical City for National Guard, Riyadh, Saudi Arabia
| | - H A Azim
- Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico
| | | | - M J Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal
| | - G Curigliano
- European Institute of Oncology IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - K A Gelmon
- British Columbia Cancer, Vancouver, Canada
| | | | - N Harbeck
- Breast Center, Department of OB&GYN and CCCMunich, LMU University Hospital, Munich, Germany
| | - B Kaufman
- Sheba Medical Center, Ramat Gan, Israel
| | - S B Kim
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Q Liu
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | | | - P Poortmans
- Iridium Netwerk, Department of Radiation Oncology & University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium
| | - G Pruneri
- National Cancer Institute, IRCCS Foundation, Milan, Italy
| | - E Senkus
- Medical University of Gdansk, Gdansk, Poland
| | - B Sirohi
- Max Institute of Cancer Care, New Delhi and Gurgaon, India
| | - T Spanic
- Europa Donna Slovenia, Ljubljana, Slovenia
| | - V Sulosaari
- European Oncology Nursing Society (EONS) and Turku University of Applied Sciences, Turku, Finland
| | - F Peccatori
- European Institute of Oncology IRCCS, Milan; European Institute of Oncology IRCCS & European School of Oncology, Milan, Italy
| | - O Pagani
- Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Vaud, Geneva University Hospitals, Lugano University, Swiss Group for Clinical Cancer Research (SAKK), Lugano, Switzerland
| |
Collapse
|
7
|
Weber WP, Shaw J, Pusic A, Wyld L, Morrow M, King T, Mátrai Z, Heil J, Fitzal F, Potter S, Rubio IT, Cardoso MJ, Gentilini OD, Galimberti V, Sacchini V, Rutgers EJT, Benson J, Allweis TM, Haug M, Paulinelli RR, Kovacs T, Harder Y, Gulluoglu BM, Gonzalez E, Faridi A, Elder E, Dubsky P, Blohmer JU, Bjelic-Radisic V, Barry M, Hay SD, Bowles K, French J, Reitsamer R, Koller R, Schrenk P, Kauer-Dorner D, Biazus J, Brenelli F, Letzkus J, Saccilotto R, Joukainen S, Kauhanen S, Karhunen-Enckell U, Hoffmann J, Kneser U, Kühn T, Kontos M, Tampaki EC, Carmon M, Hadar T, Catanuto G, Garcia-Etienne CA, Koppert L, Gouveia PF, Lagergren J, Svensjö T, Maggi N, Kappos EA, Schwab FD, Castrezana L, Steffens D, Krol J, Tausch C, Günthert A, Knauer M, Katapodi MC, Bucher S, Hauser N, Kurzeder C, Mucklow R, Tsoutsou PG, Sezer A, Çakmak GK, Karanlik H, Fairbrother P, Romics L, Montagna G, Urban C, Walker M, Formenti SC, Gruber G, Zimmermann F, Zwahlen DR, Kuemmel S, El-Tamer M, Vrancken Peeters MJ, Kaidar-Person O, Gnant M, Poortmans P, de Boniface J. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. Breast 2022; 63:123-139. [PMID: 35366506 PMCID: PMC8976143 DOI: 10.1016/j.breast.2022.03.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 03/03/2022] [Accepted: 03/14/2022] [Indexed: 12/31/2022] Open
Abstract
Aim Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario. Methods A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology. Results The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR. Conclusions The panel endorsed the need for prospective, ideally randomised phase III studies and for surgical and radiation oncology teams to work together for determination of optimal sequencing and techniques for PMRT for each patient in the context of BR Autologous breast reconstruction is increasingly preferred over implants in the setting of radiation therapy. Use of patient-reported outcomes is endorsed. Shape and size of reconstructed breasts can hinder radiotherapy planning. There is a need for randomised phase III trials.
Collapse
Affiliation(s)
- Walter Paul Weber
- Breast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland.
| | - Jane Shaw
- Patient Advocacy Group, Oncoplastic Breast Consortium, Basel, Switzerland
| | - Andrea Pusic
- Brigham and Women's/Dana Farber Cancer Center, USA
| | - Lynda Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - Monica Morrow
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Tari King
- Department of Surgery, Brigham and Women's Hospital / Dana Farber Cancer Institute, USA
| | - Zoltán Mátrai
- Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary
| | - Jörg Heil
- Department of Obstetrics and Gynecology, University of Heidelberg, Medical School, Heidelberg, Germany
| | - Florian Fitzal
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Shelley Potter
- Bristol Centre for Surgical Research, Bristol Medical School, University of Bristol, Clifton, Bristol, UK
| | - Isabel T Rubio
- Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Spain
| | - Maria-Joao Cardoso
- Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, And Nova Medical School, Lisbon, Portugal
| | | | | | - Virgilio Sacchini
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Emiel J T Rutgers
- Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands
| | - John Benson
- Cambridge Breast Unit, Addenbrooke's Hospital Cambridge, Cambridge, UK; Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation TRUST, School of Medicine, Anglia Ruskin University, Cambridge, UK
| | - Tanir M Allweis
- Hadassah Medical Center & Faculty of Medicine, Hebrew University, Jerusalem, Israel
| | - Martin Haug
- Breast Center and Department of Plastic, Reconstructive, Aesthetic and Handsurgery University Hospital Basel, University of Basel, Basel, Switzerland
| | - Regis R Paulinelli
- Federal University of Goiás, Araújo Jorge Hospital, Goiás Anti-Cancer Association, Goiás, Brazil
| | - Tibor Kovacs
- Jiahui Internatioonal Hospital Shanghai, China; Guy's and St. Thomas' NHS Foundation Trust London, UK
| | - Yves Harder
- Department of Plastic, Reconstructive and Aesthetic Surgery, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
| | | | - Eduardo Gonzalez
- Departament of Mastology, Breast Unit- Instituto de Oncología Angel H Roffo, Buenos Aires Univesity. Buenos Aires, Argentina
| | - Andree Faridi
- Department of Senology/Breast Center, University Hospital Bonn, Germany
| | - Elisabeth Elder
- Westmead Breast Cancer Institute, Westmead Hospital, University of Sydney, Australia
| | - Peter Dubsky
- Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Breast Center, Hirslanden Clinic St. Anna, Lucerne, Switzerland
| | - Jens-Uwe Blohmer
- Department of Gynecology and Breast Center, Charité University Hospital, Berlin, Germany
| | - Vesna Bjelic-Radisic
- Breast Unit, Helios University Hospital, University Witten/Herdecke, Wuppertal, Germany
| | - Mitchel Barry
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - Susanne Dieroff Hay
- Patient Advocacy Group, Oncoplastic Breast Consortium, President, the Swedish Breast Cancer Association, Stockholm, Sweden
| | - Kimberly Bowles
- Patient Advocacy Group, Oncoplastic Breast Consortium, Not Putting on A Shirt, Pittsburgh, USA
| | - James French
- Westmead Breast Cancer Institute, Westmead Hospital, University of Sydney, Australia
| | - Roland Reitsamer
- Breast Center Salzburg, University Clinic Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - Rupert Koller
- Department of Plastic, Aesthetic and Reconstructive Surgery, Vienna Health Services, Clinic Landstrasse and Clinic Ottakring, Vienna, Austria
| | - Peter Schrenk
- Breast Cancer Center, Kepler University Hospital, Linz, Austria
| | | | - Jorge Biazus
- Division of Breast Surgery, Universidade Federal Do Rio Grande Do Sul (UFRGS), Porto Alegre, Brazil
| | - Fabricio Brenelli
- Breast Oncology Division, University of Campinas, Campinas, São Paulo, Brazil
| | - Jaime Letzkus
- San Borja Arriaran Clinical Hospital, University of Chile, Chile
| | | | | | - Susanna Kauhanen
- Department of Plastic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Ulla Karhunen-Enckell
- Tampere University Hospital, Department of Surgery and Tays Cancer Center, Tampere, Finland
| | - Juergen Hoffmann
- Breast Center, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Ulrich Kneser
- Department of Hand, Plastic and Reconstructive Surgery - Burn Center, BG Trauma Center Ludwigshafen/Rhine, Hand and Plastic Surgery, University Heidelberg, Heidelberg, Germany
| | - Thorsten Kühn
- Interdisciplinary Breast Center, Klinikum Esslingen, Germany
| | | | - Ekaterini Christina Tampaki
- Department of Plastic, Reconstructive Surgeryand Burn Unit, KAT Athens Hospital and Trauma Center, Athens, Greece
| | | | - Tal Hadar
- Hadassah Medical Center & Faculty of Medicine, Hebrew University, Jerusalem, Israel
| | - Giuseppe Catanuto
- Multidisciplinary Breast Unit, Azienda Ospedaliera Cannizzaro, Catania, Italy
| | | | - Linetta Koppert
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Pedro F Gouveia
- Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, And Nova Medical School, Lisbon, Portugal
| | - Jakob Lagergren
- Department of Surgery, Capio St Goran's Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Tor Svensjö
- Department of Surgery, Central Hospital, Kristianstad, Sweden
| | - Nadia Maggi
- Breast Center, University Hospital Basel, Basel, Switzerland
| | - Elisabeth A Kappos
- Breast Center and Department of Plastic, Reconstructive, Aesthetic and Handsurgery University Hospital Basel, University of Basel, Basel, Switzerland
| | | | | | - Daniel Steffens
- Breast Center, University Hospital Basel, Basel, Switzerland
| | - Janna Krol
- Breast Center, University Hospital Basel, Basel, Switzerland
| | | | | | - Michael Knauer
- Breast Center Eastern Switzerland, St. Gallen, Switzerland
| | - Maria C Katapodi
- University of Basel, Basel, Switzerland; Patient Advocacy Group, Oncoplastic Breast Consortium, Basel, Switzerland
| | - Susanne Bucher
- Breast Center, Lucerne Cantonal Hospital, Lucerne, Switzerland
| | - Nik Hauser
- Breast Center, Hirslanden Clinic Aarau, Aarau, Frauenarztzentrum Aargau AG, Baden, Switzerland
| | - Christian Kurzeder
- Breast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland
| | - Rosine Mucklow
- Patient Advocacy Group, Oncoplastic Breast Consortium, Basel, Switzerland
| | - Pelagia G Tsoutsou
- University Hospital Geneva, University of Geneva, Faculty of Medicine, Geneva, Switzerland
| | - Atakan Sezer
- Department of Surgery, Trakya University Medical School Hospital, Turkey
| | - Güldeniz Karadeniz Çakmak
- Department of Surgery, The School of Medicine, Zonguldak Bulent Ecevit University, Zonguldak, Turkey
| | | | - Patricia Fairbrother
- Patient Advocacy Group, Oncoplastic Breast Consortium, Breakthrough Breast Cancer, Association Breast Surgery UKBCC, Kedleston, UK
| | - Laszlo Romics
- Department of Surgery, New Victoria Hospital, Glasgow, UK
| | - Giacomo Montagna
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Cicero Urban
- Breast Unit, Hospital Nossa Senhora Das Graças, Curitiba, Brazil
| | - Melanie Walker
- Breast Endocrine and General Surgery Unit, The Alfred, Melbourne, Australia; Breast Surgeons of Australia and New Zealand (BreastSurgANZ), Australia
| | - Silvia C Formenti
- Department of Radiation Oncology and Meyer Cancer Center, Weill Cornell Medicine, USA
| | - Guenther Gruber
- Institute for Radiotherapy, Klinik Hirslanden, 8032, Zurich, Switzerland; University of Berne, 3000, Bern, Switzerland
| | - Frank Zimmermann
- Clinic of Radiation Oncology, University Hospital Basel, Basel, Switzerland
| | - Daniel Rudolf Zwahlen
- Department of Radiation Oncology, Cantonal Hospital of Winterthur, Winterthur, Switzerland
| | - Sherko Kuemmel
- Department of Gynecology and Breast Center, Charité University Hospital, Berlin, Germany; Breast Unit, Kliniken Essen-Mitte, Germany
| | - Mahmoud El-Tamer
- Breast Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Marie Jeanne Vrancken Peeters
- Department of Surgical Oncology Netherlands Cancer Institute, Antoni van Leeuwenhoek & Amsterdam University Medical Center, Netherlands
| | - Orit Kaidar-Person
- Breast Radiation Therapy Unit, Sheba Tel Hashomer, Ramat Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Michael Gnant
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Philip Poortmans
- Iridium Netwerk and University of Antwerp, Wilrijk-Antwerpen, Belgium
| | - Jana de Boniface
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Surgery, Capio St Göran's Hospital, Stockholm, Sweden
| |
Collapse
|
8
|
Affiliation(s)
- Maria-Joao Cardoso
- Breast Unit Champalimaud Clinical Center, Champalimaud Foundation, And Nova Medical School, Lisbon, Portugal.
| | - Kefah Mokbel
- The London Breast Institute, Princess Grace Hospital, London, W1U 5NY, UK
| |
Collapse
|
9
|
Kläser K, Varsavsky T, Markiewicz P, Vercauteren T, Hammers A, Atkinson D, Thielemans K, Hutton B, Cardoso MJ, Ourselin S. Imitation learning for improved 3D PET/MR attenuation correction. Med Image Anal 2021; 71:102079. [PMID: 33951598 PMCID: PMC7611431 DOI: 10.1016/j.media.2021.102079] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Revised: 04/01/2021] [Accepted: 04/06/2021] [Indexed: 12/24/2022]
Abstract
The assessment of the quality of synthesised/pseudo Computed Tomography (pCT) images is commonly measured by an intensity-wise similarity between the ground truth CT and the pCT. However, when using the pCT as an attenuation map (μ-map) for PET reconstruction in Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) minimising the error between pCT and CT neglects the main objective of predicting a pCT that when used as μ-map reconstructs a pseudo PET (pPET) which is as similar as possible to the gold standard CT-derived PET reconstruction. This observation motivated us to propose a novel multi-hypothesis deep learning framework explicitly aimed at PET reconstruction application. A convolutional neural network (CNN) synthesises pCTs by minimising a combination of the pixel-wise error between pCT and CT and a novel metric-loss that itself is defined by a CNN and aims to minimise consequent PET residuals. Training is performed on a database of twenty 3D MR/CT/PET brain image pairs. Quantitative results on a fully independent dataset of twenty-three 3D MR/CT/PET image pairs show that the network is able to synthesise more accurate pCTs. The Mean Absolute Error on the pCT (110.98 HU ± 19.22 HU) compared to a baseline CNN (172.12 HU ± 19.61 HU) and a multi-atlas propagation approach (153.40 HU ± 18.68 HU), and subsequently lead to a significant improvement in the PET reconstruction error (4.74% ± 1.52% compared to baseline 13.72% ± 2.48% and multi-atlas propagation 6.68% ± 2.06%).
Collapse
Affiliation(s)
- Kerstin Kläser
- Department of Medical Physics & Biomedical Engineering, University College London, London WC1E 6BT, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK.
| | - Thomas Varsavsky
- Department of Medical Physics & Biomedical Engineering, University College London, London WC1E 6BT, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK
| | - Pawel Markiewicz
- Department of Medical Physics & Biomedical Engineering, University College London, London WC1E 6BT, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK
| | - Tom Vercauteren
- School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK
| | - Alexander Hammers
- School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK; Kings College London & GSTT PET Centre, St. Thomas Hospital, London, UK
| | - David Atkinson
- Centre for Medical Imaging, University College London, London W1W 7TS, UK
| | - Kris Thielemans
- Institute of Nuclear Medicine, University College London, London NW1 2BU, UK
| | - Brian Hutton
- Institute of Nuclear Medicine, University College London, London NW1 2BU, UK
| | - M J Cardoso
- School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK
| | - Sébastien Ourselin
- School of Biomedical Engineering & Imaging Sciences, King's College London, London SE1 7EH, UK
| |
Collapse
|
10
|
Goodkin O, Prados F, Vos SB, Pemberton H, Collorone S, Hagens MHJ, Cardoso MJ, Yousry TA, Thornton JS, Sudre CH, Barkhof F. FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. Neuroimage Clin 2020; 29:102542. [PMID: 33418171 PMCID: PMC7804983 DOI: 10.1016/j.nicl.2020.102542] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 12/20/2020] [Indexed: 11/18/2022]
Abstract
Background MRI assessment in multiple sclerosis (MS) focuses on the presence of typical white matter (WM) lesions. Neurodegeneration characterised by brain atrophy is recognised in the research field as an important prognostic factor. It is not routinely reported clinically, in part due to difficulty in achieving reproducible measurements. Automated MRI quantification of WM lesions and brain volume could provide important clinical monitoring data. In general, lesion quantification relies on both T1 and FLAIR input images, while tissue volumetry relies on T1. However, T1-weighted scans are not routinely included in the clinical MS protocol, limiting the utility of automated quantification. Objectives We address an aspect of this important translational challenge by assessing the performance of FLAIR-only lesion and brain segmentation, against a conventional approach requiring multi-contrast acquisition. We explore whether FLAIR-only grey matter (GM) segmentation yields more variability in performance compared with two-channel segmentation; whether this is related to field strength; and whether the results meet a level of clinical acceptability demonstrated by the ability to reproduce established biological associations. Methods We used a multicentre dataset of subjects with a CIS suggestive of MS scanned at 1.5T and 3T in the same week. WM lesions were manually segmented by two raters, ‘manual 1′ guided by consensus reading of CIS-specific lesions and ‘manual 2′ by any WM hyperintensity. An existing brain segmentation method was adapted for FLAIR-only input. Automated segmentation of WM hyperintensity and brain volumes were performed with conventional (T1/T1 + FLAIR) and FLAIR-only methods. Results WM lesion volumes were comparable at 1.5T between ‘manual 2′ and FLAIR-only methods and at 3T between ‘manual 2′, T1 + FLAIR and FLAIR-only methods. For cortical GM volume, linear regression measures between conventional and FLAIR-only segmentation were high (1.5T: α = 1.029, R2 = 0.997, standard error (SE) = 0.007; 3T: α = 1.019, R2 = 0.998, SE = 0.006). Age-associated change in cortical GM volume was a significant covariate in both T1 (p = 0.001) and FLAIR-only (p = 0.005) methods, confirming the expected relationship between age and GM volume for FLAIR-only segmentations. Conclusions FLAIR-only automated segmentation of WM lesions and brain volumes were consistent with results obtained through conventional methods and had the ability to demonstrate biological effects in our study population. Imaging protocol harmonisation and validation with other MS phenotypes could facilitate the integration of automated WM lesion volume and brain atrophy analysis as clinical tools in radiological MS reporting.
Collapse
Affiliation(s)
- O Goodkin
- Centre for Medical Image Computing (CMIC), University College London, London, United Kingdom; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
| | - F Prados
- Centre for Medical Image Computing (CMIC), University College London, London, United Kingdom; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; eHealth Centre, Universitat Oberta de Catalunya, Barcelona, Spain
| | - S B Vos
- Centre for Medical Image Computing (CMIC), University College London, London, United Kingdom; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom
| | - H Pemberton
- Centre for Medical Image Computing (CMIC), University College London, London, United Kingdom; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom
| | - S Collorone
- NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London (UCL), London, United Kingdom
| | - M H J Hagens
- MS Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - M J Cardoso
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
| | - T A Yousry
- Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom
| | - J S Thornton
- Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom
| | - C H Sudre
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom; Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom
| | - F Barkhof
- Centre for Medical Image Computing (CMIC), University College London, London, United Kingdom; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom; Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands
| |
Collapse
|
11
|
Kaidar-Person O, Boersma LJ, Poortmans P, Sklair-Levy M, Offersen BV, Cardoso MJ, de Ruysscher D. Residual Glandular Breast Tissue After Mastectomy: A Systematic Review. Ann Surg Oncol 2020; 27:2288-2296. [PMID: 32390098 DOI: 10.1245/s10434-020-08516-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Indexed: 12/22/2022]
Abstract
BACKGROUND The goal of mastectomy is remove all of the glandular breast tissue (BGT) without compromising skin flaps viability. The purpose of this systematic review was to localize and/or estimate the amount of residual BGT (rBGT) after mastectomy and to identify factors that could be related to rBGT and/or residual disease. METHODS We conducted a PubMed search. The report was subdivided according to the method used to evaluate the presence of rBGT. A total of 16 publications were included in our final report. Two main methods for identifying rBGT included imaging (i.e., MRI scan) and histological evaluation at the time of mastectomy. RESULTS The rate of rBGT was reported in up to 100% of the patients and was found to be associated mainly with the type of surgical resection, indication, and surgeon's expertise. Residual breast tissue can be found in all areas of the remaining chest wall, mostly in the skin-flaps, and more frequently underneath the nipple-areola complex.
Collapse
Affiliation(s)
- Orit Kaidar-Person
- Breast Radiation Unit at Sheba Medical Center, Ramat Gan, Israel. .,GROW-School for Oncology and Developmental Biology or GROW, Maastricht University, Maastricht, The Netherlands.
| | - Liesbeth J Boersma
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
| | | | - Miri Sklair-Levy
- Meirav Breast Center, Department of Diagnostic Imaging, Chaim Sheba Medical Center and the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Birgitte Vrou Offersen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - Maria-Joao Cardoso
- Breast Unit, Champalimaud Clinical Centre, Champalilaud Foundation and Nova Medical School, Lisbon, Portugal
| | - Dirk de Ruysscher
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
| |
Collapse
|
12
|
Kaidar-Person O, Cardoso MJ. ASO Author Reflections: Residual Breast Tissue After Skin- and Nipple-Sparing Mastectomies: A Matter of Concern or a Point for Improvement/Action? Ann Surg Oncol 2020; 27:2297-2298. [DOI: 10.1245/s10434-020-08532-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Indexed: 12/17/2022]
|
13
|
Biganzoli L, Marotti L, Cardoso MJ, Cataliotti L, Curigliano G, Cuzick J, Goldhirsch A, Leidenius M, Mansel R, Markopoulos C, Wyld L, Rubio IT. European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Breast Care (Basel) 2019; 14:359-365. [PMID: 31933581 PMCID: PMC6940462 DOI: 10.1159/000503603] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Accepted: 09/22/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND EUSOMA undertook the commitment of defining the requirements for a specialist breast centre, which has become the reference document for the implementation of breast centres. SUMMARY The EUSOMA requirements for a specialist breast centre give clear indications regarding the requisite caseload, dedicated team composition (core and non-core team), organisation, availability of services and equipment throughout the patient pathway, quality control, and application of a multidisciplinary approach. The minimum number of cases is 150 newly diagnosed breast cancer cases per year. Based on the EUSOMA requirements, a voluntary and accredited certification scheme has been developed. In Europe, other voluntary certification schemes are available, such as those developed by the German Cancer Society and German Society for Breast Disease, the National Cancer Peer Review Programme in the UK, and the "label de qualité" established by the Swiss Anticancer League and the Swiss Senology Society. The European Commission Initiative on Breast Cancer (ECIBC) has overseen the development of a European Quality Assurance Scheme. KEY MESSAGES Nearly 20 years after the initial publication of the EUSOMA requirements, ensuring that all breast cancer patients in Europe are treated only in certified breast centres should be considered a high priority and eventually achieved through collaborative efforts.
Collapse
Affiliation(s)
| | | | - Maria-Joao Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal
| | | | - Giuseppe Curigliano
- Department of Oncology and Haematology, University of Milan, Milan, Italy
- IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - Jack Cuzick
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom
| | - Aaron Goldhirsch
- International Breast Cancer Study Group, Bern, Switzerland
- MultiMedica, Milan, Italy
| | - Marjut Leidenius
- Breast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
| | - Robert Mansel
- Cardiff University School of Medicine, Cardiff, United Kingdom
| | | | - Lynda Wyld
- Department of Oncology and Metabolism, University of Sheffield, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom
| | - Isabel T. Rubio
- Breast Surgical Oncology Unit, Clinica Universidad de Navarra, Madrid, Spain
- Universidad de Navarra, Pamplona, Spain
| |
Collapse
|
14
|
Cardoso MJ, Biganzoli L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Kovacs T, Wyld L. Corrigendum to "About the French prohibition of textured breast implants: Is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position" [Breast 46 (August 2019) 95-96]. Breast 2019; 48:103. [PMID: 31706464 DOI: 10.1016/j.breast.2019.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.
| | - L Biganzoli
- Breast Unit, Nuovo Ospedale di Prato, Prato, Italy
| | - I T Rubio
- Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain
| | - M Leidenius
- Breast Surgery Unit, Comprehensive Cancer Center Helsinki University Hospital, Helsinki, Finland
| | - G Curigliano
- IEO, European Institute of Oncology IRCCS, Italy; University of Milano, Milan, Italy
| | - B Cutuli
- Institut du Cancer Courlancy, Reims, France
| | | | - T Kovacs
- Surgical Oncologist at Guy's and St. Thomas' NHS Foundation Trust, London, UK
| | - L Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| |
Collapse
|
15
|
Cardoso MJ, Wyld L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L. Corrigendum to "EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants" [Breast 44 (April 2019) 90-93]. Breast 2019; 48:102. [PMID: 31706463 DOI: 10.1016/j.breast.2019.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.
| | - L Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - I T Rubio
- Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain
| | - M Leidenius
- Breast Surgery Unit, Comprehensive Cancer Center Helsinki University Hospital, Helsinki, Finland
| | - G Curigliano
- IEO, European Institute of Oncology IRCCS, Italy; University of Milano, Milan, Italy
| | - B Cutuli
- Institut du Cancer Courlancy, Reims, France
| | | | - L Biganzoli
- Breast Unit, Nuovo Ospedale di Prato, Prato, Italy
| |
Collapse
|
16
|
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29:1634-1657. [PMID: 30032243 PMCID: PMC7360146 DOI: 10.1093/annonc/mdy192] [Citation(s) in RCA: 761] [Impact Index Per Article: 126.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology (ESO), European Society for Medical Oncology (ESMO) and Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
| | - E Senkus
- European Society for Medical Oncology (ESMO) and Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - A Costa
- European School of Oncology, Milan, Italy
| | | | - M Aapro
- Oncology Department, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - B Aguilar Lopez
- Direction Office, ULACCAM (Union Latinoamericana Contra el Cáncer de la Mujer), Mexico DF, Mexico
| | - C H Barrios
- Department of Oncology, PURCS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - L Biganzoli
- European Society of Breast Cancer Specialists (EUSOMA) and Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | | | - M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- Department of Oncology, Vall d' Hebron University, Barcelona, Spain
| | - G Curigliano
- Division of Early Drug Development, Department of Oncology and Hemato-Oncology, European Institute of Oncology, University of Milano, Milano, Italy
| | - V Diéras
- Gynaecology and Breast Department, Centre Eugène Marquis, Rennes, France
| | - N S El Saghir
- Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Eniu
- Breast Cancer Department, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | | | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - S Koppikar
- Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India
| | - I E Krop
- Breast Oncology Center Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - G Nakigudde
- Advocacy Department, UWOCASO (Uganda Women's Cancer Support Organization), Kampala, Uganda
| | - B V Offersen
- European Society of Radiation Oncology (ESTRO) and Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Cancer Institute Hospital, Breast Oncology Centre, Tokyo, Japan
| | - O Pagani
- Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), International Breast Cancer Study Group (IBCSG), Bellinzona, Switzerland
| | - S Paluch-Shimon
- Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel
| | - F Penault-Llorca
- Department of Pathology, Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - A Prat
- IDIBAPS (Institut d'Investigacions Biomèdiques August Pi iSunyer), Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Oncology Division, Stanford University Medical Center, Stanford, USA
| | - D Spence
- Policy Department, Breast Cancer Network Australia, Camberwell, VIC, Australia
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Department, Sandton Oncology Centre, Johannesburg, South Africa
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York
| | - E P Winer
- Dana-Farber Cancer Institute, Susan Smith Center for Women's Cancers, Breast Oncology Center, Boston, USA
| |
Collapse
|
17
|
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 2018; 27:v103-v110. [PMID: 27664246 DOI: 10.1093/annonc/mdw327] [Citation(s) in RCA: 244] [Impact Index Per Article: 40.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Affiliation(s)
- S Paluch-Shimon
- Division of Oncology and the Dr Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - C Sessa
- Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | - J Balmana
- Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, Spain
| | - M J Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - F Gilbert
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | | |
Collapse
|
18
|
Kieselmann JP, Kamerling CP, Burgos N, Menten MJ, Fuller CD, Nill S, Cardoso MJ, Oelfke U. Geometric and dosimetric evaluations of atlas-based segmentation methods of MR images in the head and neck region. Phys Med Biol 2018; 63:145007. [PMID: 29882749 PMCID: PMC6296440 DOI: 10.1088/1361-6560/aacb65] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 06/01/2018] [Accepted: 06/08/2018] [Indexed: 11/19/2022]
Abstract
Owing to its excellent soft-tissue contrast, magnetic resonance (MR) imaging has found an increased application in radiation therapy (RT). By harnessing these properties for treatment planning, automated segmentation methods can alleviate the manual workload burden to the clinical workflow. We investigated atlas-based segmentation methods of organs at risk (OARs) in the head and neck (H&N) region using one approach that selected the most similar atlas from a library of segmented images and two multi-atlas approaches. The latter were based on weighted majority voting and an iterative atlas-fusion approach called STEPS. We built the atlas library from pre-treatment T1-weighted MR images of 12 patients with manual contours of the parotids, spinal cord and mandible, delineated by a clinician. Following a leave-one-out cross-validation strategy, we measured the geometric accuracy by calculating Dice similarity coefficients (DSC), standard and 95% Hausdorff distances (HD and HD95), and the mean surface distance (MSD), whereby the manual contours served as the gold standard. To benchmark the algorithm, we determined the inter-observer variability (IOV) between three observers. To investigate the dosimetric effect of segmentation inaccuracies, we implemented an auto-planning strategy within the treatment planning system Monaco (Elekta AB, Stockholm, Sweden). For each set of auto-segmented OARs, we generated a plan for a 9-beam step and shoot intensity modulated RT treatment, designed according to our institution's clinical H&N protocol. Superimposing the dose distributions on the gold standard OARs, we calculated dose differences to OARs caused by delineation differences between auto-segmented and gold standard OARs. We investigated the correlations between geometric and dosimetric differences. The mean DSC was larger than 0.8 and the mean MSD smaller than 2 mm for the multi-atlas approaches, resulting in a geometric accuracy comparable to previously published results and within the range of the IOV. While dosimetric differences could be as large as 23% of the clinical goal, treatment plans fulfilled all imposed clinical goals for the gold standard OARs. Correlations between geometric and dosimetric measures were low with R2 < 0.5. The geometric accuracy and the ability to achieve clinically acceptable treatment plans indicate the suitability of using atlas-based contours for RT treatment planning purposes. The low correlations between geometric and dosimetric measures suggest that geometric measures alone are not sufficient to predict the dosimetric impact of segmentation inaccuracies on treatment planning for the data utilised in this study.
Collapse
Affiliation(s)
- J P Kieselmann
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - C P Kamerling
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - N Burgos
- University
College London, Centre for Medical Image Computing, London,
United Kingdom
- Inria, Aramis project-team, Institut du Cerveau et de la Moelle
épinière, Sorbonne Université, Paris,
France
| | - M J Menten
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - C D Fuller
- Department of Radiation Oncology,
MD Anderson Cancer Center,
Houston, TX, United States of America
| | - S Nill
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - M J Cardoso
- University
College London, Centre for Medical Image Computing, London,
United Kingdom
- School of
Biomedical Engineering and Imaging Sciences, King’s College,
London, United Kingdom
| | - U Oelfke
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| |
Collapse
|
19
|
Kieselmann JP, Kamerling CP, Burgos N, Menten MJ, Fuller CD, Nill S, Cardoso MJ, Oelfke U. Geometric and dosimetric evaluations of atlas-based segmentation methods of MR images in the head and neck region. Phys Med Biol 2018; 63:145007. [PMID: 29882749 PMCID: PMC6296440 DOI: 10.1088/1361-6560/aacb65;145007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Owing to its excellent soft-tissue contrast, magnetic resonance (MR) imaging has found an increased application in radiation therapy (RT). By harnessing these properties for treatment planning, automated segmentation methods can alleviate the manual workload burden to the clinical workflow. We investigated atlas-based segmentation methods of organs at risk (OARs) in the head and neck (H&N) region using one approach that selected the most similar atlas from a library of segmented images and two multi-atlas approaches. The latter were based on weighted majority voting and an iterative atlas-fusion approach called STEPS. We built the atlas library from pre-treatment T1-weighted MR images of 12 patients with manual contours of the parotids, spinal cord and mandible, delineated by a clinician. Following a leave-one-out cross-validation strategy, we measured the geometric accuracy by calculating Dice similarity coefficients (DSC), standard and 95% Hausdorff distances (HD and HD95), and the mean surface distance (MSD), whereby the manual contours served as the gold standard. To benchmark the algorithm, we determined the inter-observer variability (IOV) between three observers. To investigate the dosimetric effect of segmentation inaccuracies, we implemented an auto-planning strategy within the treatment planning system Monaco (Elekta AB, Stockholm, Sweden). For each set of auto-segmented OARs, we generated a plan for a 9-beam step and shoot intensity modulated RT treatment, designed according to our institution's clinical H&N protocol. Superimposing the dose distributions on the gold standard OARs, we calculated dose differences to OARs caused by delineation differences between auto-segmented and gold standard OARs. We investigated the correlations between geometric and dosimetric differences. The mean DSC was larger than 0.8 and the mean MSD smaller than 2 mm for the multi-atlas approaches, resulting in a geometric accuracy comparable to previously published results and within the range of the IOV. While dosimetric differences could be as large as 23% of the clinical goal, treatment plans fulfilled all imposed clinical goals for the gold standard OARs. Correlations between geometric and dosimetric measures were low with R2 < 0.5. The geometric accuracy and the ability to achieve clinically acceptable treatment plans indicate the suitability of using atlas-based contours for RT treatment planning purposes. The low correlations between geometric and dosimetric measures suggest that geometric measures alone are not sufficient to predict the dosimetric impact of segmentation inaccuracies on treatment planning for the data utilised in this study.
Collapse
Affiliation(s)
- J P Kieselmann
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom,
| | - C P Kamerling
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - N Burgos
- University
College London, Centre for Medical Image Computing, London,
United Kingdom,Inria, Aramis project-team, Institut du Cerveau et de la Moelle
épinière, Sorbonne Université, Paris,
France
| | - M J Menten
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - C D Fuller
- Department of Radiation Oncology,
MD Anderson Cancer Center,
Houston, TX, United States of America
| | - S Nill
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| | - M J Cardoso
- University
College London, Centre for Medical Image Computing, London,
United Kingdom,School of
Biomedical Engineering and Imaging Sciences, King’s College,
London, United Kingdom
| | - U Oelfke
- Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust, London, United
Kingdom
| |
Collapse
|
20
|
Sudre CH, Gomez Anson B, Davagnanam I, Schmitt A, Mendelson AF, Prados F, Smith L, Atkinson D, Hughes AD, Chaturvedi N, Cardoso MJ, Barkhof F, Jaeger HR, Ourselin S. Bullseye's representation of cerebral white matter hyperintensities. J Neuroradiol 2018; 45:114-122. [PMID: 29132940 PMCID: PMC5867449 DOI: 10.1016/j.neurad.2017.10.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Revised: 10/03/2017] [Accepted: 10/17/2017] [Indexed: 12/21/2022]
Abstract
BACKGROUND AND PURPOSE Visual rating scales have limited capacities to depict the regional distribution of cerebral white matter hyperintensities (WMH). We present a regional-zonal volumetric analysis alongside a visualization tool to compare and deconstruct visual rating scales. MATERIALS AND METHODS 3D T1-weighted, T2-weighted spin-echo and FLAIR images were acquired on a 3T system, from 82 elderly participants in a population-based study. Images were automatically segmented for WMH. Lobar boundaries and distance to ventricular surface were used to define white matter regions. Regional-zonal WMH loads were displayed using bullseye plots. Four raters assessed all images applying three scales. Correlations between visual scales and regional WMH as well as inter and intra-rater variability were assessed. A multinomial ordinal regression model was used to predict scores based on regional volumes and global WMH burdens. RESULTS On average, the bullseye plot depicted a right-left symmetry in the distribution and concentration of damage in the periventricular zone, especially in frontal regions. WMH loads correlated well with the average visual rating scores (e.g. Kendall's tau [Volume, Scheltens]=0.59 CI=[0.53 0.62]). Local correlations allowed comparison of loading patterns between scales and between raters. Regional measurements had more predictive power than global WMH burden (e.g. frontal caps prediction with local features: ICC=0.67 CI=[0.53 0.77], global volume=0.50 CI=[0.32 0.65], intra-rater=0.44 CI=[0.23 0.60]). CONCLUSION Regional-zonal representation of WMH burden highlights similarities and differences between visual rating scales and raters. The bullseye infographic tool provides a simple visual representation of regional lesion load that can be used for rater calibration and training.
Collapse
Affiliation(s)
- C H Sudre
- Translational Imaging Group, CMIC, Department of Medical Physics and Biomedical Engineering, University College London, Room 8.04 8th floor Malet Place Engineering Building, 2, Malet Place, WC1E 7JE London, UK; Dementia Research Centre, UCL Institute of Neurology, WC1N 3BG London, UK.
| | - B Gomez Anson
- Santa Creu i Sant Pau Hospital, Universitat Autonòma Barcelona, 08041 Barcelona, Spain.
| | - I Davagnanam
- Lysholm Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, Queen Square, WCN1 3BG London, UK; Brain Repair and Rehabilitation, UCL Institute of Neurology, WC1N 3BG London, UK.
| | - A Schmitt
- Lysholm Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, Queen Square, WCN1 3BG London, UK.
| | - A F Mendelson
- Translational Imaging Group, CMIC, Department of Medical Physics and Biomedical Engineering, University College London, Room 8.04 8th floor Malet Place Engineering Building, 2, Malet Place, WC1E 7JE London, UK.
| | - F Prados
- Translational Imaging Group, CMIC, Department of Medical Physics and Biomedical Engineering, University College London, Room 8.04 8th floor Malet Place Engineering Building, 2, Malet Place, WC1E 7JE London, UK.
| | - L Smith
- Cardiometabolic Phenotyping Group, UCL Institute of Cardiovascular Science, W1CE 6HX London, UK.
| | - D Atkinson
- Centre for Medical Imaging, UCL Faculty of Medical Science, NW1 2PG London, UK.
| | - A D Hughes
- Cardiometabolic Phenotyping Group, UCL Institute of Cardiovascular Science, W1CE 6HX London, UK.
| | - N Chaturvedi
- Cardiometabolic Phenotyping Group, UCL Institute of Cardiovascular Science, W1CE 6HX London, UK.
| | - M J Cardoso
- Translational Imaging Group, CMIC, Department of Medical Physics and Biomedical Engineering, University College London, Room 8.04 8th floor Malet Place Engineering Building, 2, Malet Place, WC1E 7JE London, UK; Dementia Research Centre, UCL Institute of Neurology, WC1N 3BG London, UK.
| | - F Barkhof
- Translational Imaging Group, CMIC, Department of Medical Physics and Biomedical Engineering, University College London, Room 8.04 8th floor Malet Place Engineering Building, 2, Malet Place, WC1E 7JE London, UK; Brain Repair and Rehabilitation, UCL Institute of Neurology, WC1N 3BG London, UK.
| | - H R Jaeger
- Lysholm Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, Queen Square, WCN1 3BG London, UK; Brain Repair and Rehabilitation, UCL Institute of Neurology, WC1N 3BG London, UK.
| | - S Ourselin
- Translational Imaging Group, CMIC, Department of Medical Physics and Biomedical Engineering, University College London, Room 8.04 8th floor Malet Place Engineering Building, 2, Malet Place, WC1E 7JE London, UK; Dementia Research Centre, UCL Institute of Neurology, WC1N 3BG London, UK.
| |
Collapse
|
21
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:3111. [PMID: 28327998 PMCID: PMC5834023 DOI: 10.1093/annonc/mdx036] [Citation(s) in RCA: 136] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
22
|
Gentilini OD, Cardoso MJ, Poortmans P. Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients. Breast 2017. [DOI: 10.1016/j.breast.2017.06.004] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
23
|
Batista PSC, Menezes CB, Carvalho AJ, Portugal AF, Bastos EA, Cardoso MJ, Santos CV, Julio MPM. Performance of grain sorghum hybrids under drought stress using GGE biplot analyses. Genet Mol Res 2017; 16:gmr-16-03-gmr.16039761. [PMID: 28973741 DOI: 10.4238/gmr16039761] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The objective of this study was to estimate the adaptability and stability of grain sorghum hybrids grown under post-flowering water stress and non-stress conditions. The trials were carried out in Nova Porteirinha-MG during the season of 2014 and 2015, and in Teresina-PI in the 2014 season. Twenty-nine-grain sorghum hybrids were evaluated, in a randomized complete block design, with three replications. Plots consisted of four lines with 3 m long. The grain yield data were submitted to the individual variance analysis, having considered the effects of the hybrids as fixed and the other effects as random. The joint analysis was carried out, and when the interaction genotypes x environments was significant, the grain yield data were submitted to the adaptability and stability analysis by the GGE biplot method. A substantial reduction in the grain yield in environments with water stress was found. The highest yielding hybrids under water stress conditions in Nova Porteirinha-MG were 50A50, AG1080, AG1090, DKB550, DKB590, Jade, and BM737, and the highest yielding hybrids under the water stress in Teresina-PI were 1G282, 1G244, and A9721R. Considering all environments, the highest yielding hybrids were 1G282, DKB540, A9721R, 1G100, and AG1090.
Collapse
Affiliation(s)
- P S C Batista
- Centro de Ciências Exatas e Tecnológicas, Universidade Estadual de Montes Claros, Campus Janaúba, Janaúba, MG, Brasil
| | - C B Menezes
- Núcleo de Desenvolvimento e Recursos Genéticos, Embrapa Milho e Sorgo, Sete Lagoas, MG, Brasil
| | - A J Carvalho
- Centro de Ciências Exatas e Tecnológicas, Universidade Estadual de Montes Claros, Campus Janaúba, Janaúba, MG, Brasil
| | - A F Portugal
- Núcleo de Desenvolvimento e Recursos Genéticos, Embrapa Milho e Sorgo, Sete Lagoas, MG, Brasil
| | - E A Bastos
- Setor de Produção Vegetal, Grupo de Pesquisa e Desenvolvimento, Embrapa Meio-Norte, , Brasil
| | - M J Cardoso
- Setor de Produção Vegetal, Grupo de Pesquisa e Desenvolvimento, Embrapa Meio-Norte, , Brasil
| | - C V Santos
- Departamento de Ciências Agrárias, Universidade Federal de São João del-Rei, Campus Sete Lagoas, Sete Lagoas, MG, Brasil
| | - M P M Julio
- Departamento de Ciências Agrárias, Universidade Federal de São João del-Rei, Campus Sete Lagoas, Sete Lagoas, MG, Brasil
| |
Collapse
|
24
|
Guerreiro F, Burgos N, Dunlop A, Wong K, Petkar I, Nutting C, Harrington K, Bhide S, Newbold K, Dearnaley D, deSouza NM, Morgan VA, McClelland J, Nill S, Cardoso MJ, Ourselin S, Oelfke U, Knopf AC. Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning. Phys Med 2017; 35:7-17. [PMID: 28242137 PMCID: PMC5368286 DOI: 10.1016/j.ejmp.2017.02.017] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Revised: 01/27/2017] [Accepted: 02/14/2017] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND AND PURPOSE Computed tomography (CT) imaging is the current gold standard for radiotherapy treatment planning (RTP). The establishment of a magnetic resonance imaging (MRI) only RTP workflow requires the generation of a synthetic CT (sCT) for dose calculation. This study evaluates the feasibility of using a multi-atlas sCT synthesis approach (sCTa) for head and neck and prostate patients. MATERIAL AND METHODS The multi-atlas method was based on pairs of non-rigidly aligned MR and CT images. The sCTa was obtained by registering the MRI atlases to the patient's MRI and by fusing the mapped atlases according to morphological similarity to the patient. For comparison, a bulk density assignment approach (sCTbda) was also evaluated. The sCTbda was obtained by assigning density values to MRI tissue classes (air, bone and soft-tissue). After evaluating the synthesis accuracy of the sCTs (mean absolute error), sCT-based delineations were geometrically compared to the CT-based delineations. Clinical plans were re-calculated on both sCTs and a dose-volume histogram and a gamma analysis was performed using the CT dose as ground truth. RESULTS Results showed that both sCTs were suitable to perform clinical dose calculations with mean dose differences less than 1% for both the planning target volume and the organs at risk. However, only the sCTa provided an accurate and automatic delineation of bone. CONCLUSIONS Combining MR delineations with our multi-atlas CT synthesis method could enable MRI-only treatment planning and thus improve the dosimetric and geometric accuracy of the treatment, and reduce the number of imaging procedures.
Collapse
Affiliation(s)
- F Guerreiro
- Faculty of Sciences, University of Lisbon, Campo Grande, Portugal; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom.
| | - N Burgos
- Translational Imaging Group, Centre for Medical Imaging Computing, University College London, London, United Kingdom.
| | - A Dunlop
- Royal Marsden Hospital, London, United Kingdom
| | - K Wong
- Royal Marsden Hospital, London, United Kingdom
| | - I Petkar
- Royal Marsden Hospital, London, United Kingdom
| | - C Nutting
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - K Harrington
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - S Bhide
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - K Newbold
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - D Dearnaley
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - N M deSouza
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - V A Morgan
- Royal Marsden Hospital, London, United Kingdom
| | - J McClelland
- Centre for Medical Image Computing, Dept. Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
| | - S Nill
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom
| | - M J Cardoso
- Translational Imaging Group, Centre for Medical Imaging Computing, University College London, London, United Kingdom
| | - S Ourselin
- Translational Imaging Group, Centre for Medical Imaging Computing, University College London, London, United Kingdom
| | - U Oelfke
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - A C Knopf
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
25
|
Teodoro PE, Almeida Filho JE, Daher RF, Menezes CB, Cardoso MJ, Godinho VPC, Torres FE, Tardin FD. Identification of sorghum hybrids with high phenotypic stability using GGE biplot methodology. Genet Mol Res 2016; 15:gmr7914. [PMID: 27323167 DOI: 10.4238/gmr.15027914] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The aim of this study was to identify sorghum hybrids that have both high yield and phenotypic stability in Brazilian environments. Seven trials were conducted between February and March 2011. The experimental design was a randomized complete block with 25 treatments and three replicates. The treatments consisted of 20 simple pre-commercial hybrids and five witnesses of grain sorghum. Sorghum genotypes were analyzed by the genotype main effects + genotype environment interaction (GGE) biplot method if significant genotype x environment interaction, adaptability, and phenotypic stability were detected. GGE biplot methodology identified two groups of environments, the first composed of Água Comprida-MG, Montividiu-GO, and Vilhena- RO and the second of Guaíra-SP and Sete Lagoas-MG. The BRS 308 and 1G282 genotypes were found to have high grain yield, adaptability, and phenotypic stability and are thus indicated for cultivation in the first and second groups of environments, respectively.
Collapse
Affiliation(s)
- P E Teodoro
- Departamento de Biologia Geral, Universidade Federal de Viçosa, Viçosa, MG, Brasil
| | - J E Almeida Filho
- Departamento de Estatística, Universidade Federal de Viçosa, Viçosa, MG, Brasil
| | - R F Daher
- Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro
| | - C B Menezes
- Núcleo de Recursos Genéticos e Obtenção de Cultivares, Embrapa Milho e Sorgo, Sete Lagoas, MG, Brasil
| | - M J Cardoso
- Setor de Produção Vegetal, Embrapa Meio Norte, Teresina, PI, Brasil
| | - V P C Godinho
- Setor de Produção Vegetal, Embrapa Rondônia, Vilhena, RO, Brasil
| | - F E Torres
- Departamento de Fitotecnia, Universidade Estadual do Mato Grosso do Sul, Aquidauana, MS, Brasil
| | - F D Tardin
- Núcleo de Recursos Genéticos e Obtenção de Cultivares, Embrapa Milho e Sorgo, Sinop, MT, Brasil
| |
Collapse
|
26
|
Holmes HE, Colgan N, Ismail O, Ma D, Powell NM, O'Callaghan JM, Harrison IF, Johnson RA, Murray TK, Ahmed Z, Heggenes M, Fisher A, Cardoso MJ, Modat M, Walker-Samuel S, Fisher EMC, Ourselin S, O'Neill MJ, Wells JA, Collins EC, Lythgoe MF. Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiol Aging 2016; 39:184-94. [PMID: 26923415 PMCID: PMC4782737 DOI: 10.1016/j.neurobiolaging.2015.12.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Revised: 12/08/2015] [Accepted: 12/09/2015] [Indexed: 01/30/2023]
Abstract
Mouse models of Alzheimer's disease have served as valuable tools for investigating pathogenic mechanisms relating to neurodegeneration, including tau-mediated and neurofibrillary tangle pathology-a major hallmark of the disease. In this work, we have used multiparametric magnetic resonance imaging (MRI) in a longitudinal study of neurodegeneration in the rTg4510 mouse model of tauopathy, a subset of which were treated with doxycycline at different time points to suppress the tau transgene. Using this paradigm, we investigated the sensitivity of multiparametric MRI to both the accumulation and suppression of pathologic tau. Tau-related atrophy was discernible from 5.5 months within the cortex and hippocampus. We observed markedly less atrophy in the treated rTg4510 mice, which was enhanced after doxycycline intervention from 3.5 months. We also observed differences in amide proton transfer, cerebral blood flow, and diffusion tensor imaging parameters in the rTg4510 mice, which were significantly less altered after doxycycline treatment. We propose that these non-invasive MRI techniques offer insight into pathologic mechanisms underpinning Alzheimer's disease that may be important when evaluating emerging therapeutics targeting one of more of these processes.
Collapse
Affiliation(s)
- Holly E Holmes
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK.
| | - Niall Colgan
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Ozama Ismail
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Da Ma
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK; Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Nick M Powell
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK; Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - James M O'Callaghan
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Ian F Harrison
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Ross A Johnson
- Tailored Therapeutics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | | | | | | | | | - M J Cardoso
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Marc Modat
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | - Simon Walker-Samuel
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Elizabeth M C Fisher
- Department of Neurodegenerative Diseases, Institute of Neurology, University College London, London, UK
| | - Sebastien Ourselin
- Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK
| | | | - Jack A Wells
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| | - Emily C Collins
- Tailored Therapeutics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
| | - Mark F Lythgoe
- Division of Medicine, Centre for Advanced Biomedical Imaging, University College London, London, UK
| |
Collapse
|
27
|
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015; 26:2505-6. [PMID: 26467471 DOI: 10.1093/annonc/mdv478] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F. Breast cancer under age 40: a different approach. Curr Treat Options Oncol 2015; 16:16. [PMID: 25796377 DOI: 10.1007/s11864-015-0334-8] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Breast cancer (BC) under age 40 is a complex disease to manage due to the additionally fertility-related factors to be taken in consideration. More than 90% of young patients with BC are symptomatic. Women<40 years are more likely to develop BC with worse clinicopathological features and more aggressive subtype. This has been frequently associated with inferior outcomes. Recently, the prognostic significance of age<40 has been shown to differ according to the BC subtype, being associated with worst recurrence-free survival (RFS) and overall survival (OS) for luminal BC. The biology of BC<40 has also been explored through analysis of large genomic data set, and specific pathways overexpressed in these tumors have been identified which can lead to the development of targeted therapy in the future. A multidisciplinary tumor board should determine the optimal locoregional and systemic management strategies for every individual patient with BC before the start of any therapy including surgery. This applies to both early (early breast cancer (EBC)) and advanced (advanced breast cancer (ABC)) disease, before the start of any therapy. Mastectomy even in young patients confers no overall survival advantage when compared to breast-conserving treatment (BCT), followed by radiotherapy. Regarding axillary approach, indications are identical to other age groups. Young age is one of the most important risk factors for local recurrence after both breast-conserving surgery (BCS) and mastectomy, associated with a higher risk of distant metastasis and death. Radiation after BCS reduces local recurrence from 19.5 to 10.2% in BC patients 40 years and younger. The indications for and the choice of systemic treatment for invasive BC (both early and advanced disease) should not be based on age alone but driven by the biological characteristics of the individual tumor (including hormone receptor status, human epidermal growth factor receptor 2 (HER-2) status, grade, and proliferative activity), disease stage, and patient's comorbidities. Recommendations regarding the use of genomic profiles such as MammaPrint, Oncotype Dx, and Genomic grade index in young women are similar to the general BC population. Especially in the metastatic setting, patient preferences should always be taken into account, as the disease is incurable. The best strategy for these patients is the inclusion into well-designed, independent, prospective randomized clinical trials. Metastatic disease should always be biopsied whenever feasible for histological confirmation and reassessment of biology. Endocrine therapy is the preferred option for hormone receptor-positive disease (HR+ve), even in presence of visceral metastases, unless there is concern or proof of endocrine resistance or there is a need for rapid disease response and/or symptom control. Recommendations for chemotherapy (CT) should not differ from those for older patients with the same characteristics of the metastatic disease and its extent. Young age by itself should not be an indication to prescribe more intensive and combination CT regimens over the sequential use of monotherapy. Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) represent an important group of promising drugs in managing patients with breast cancer susceptibility gene (BRCA)-1- or BRCA-2-associated BC. Specific age-related side effects of systemic treatment (e.g., menopausal symptoms, change in body image, bone morbidity, cognitive function impairment, fertility damage, sexual dysfunction) and the social impact of diagnosis and treatment (job discrimination, taking care for children) should also be carefully addressed when planning systemic long-lasting therapy, such as endocrine therapy. Survivorship concerns for young women are different compared to older women, including issues of fertility, preservation, and pregnancy.
Collapse
Affiliation(s)
- D Ribnikar
- Medical Oncology Department, Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Wells JA, O'Callaghan JM, Holmes HE, Powell NM, Johnson RA, Siow B, Torrealdea F, Ismail O, Walker-Samuel S, Golay X, Rega M, Richardson S, Modat M, Cardoso MJ, Ourselin S, Schwarz AJ, Ahmed Z, Murray TK, O'Neill MJ, Collins EC, Colgan N, Lythgoe MF. In vivo imaging of tau pathology using multi-parametric quantitative MRI. Neuroimage 2015; 111:369-78. [PMID: 25700953 PMCID: PMC4626540 DOI: 10.1016/j.neuroimage.2015.02.023] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2014] [Revised: 02/04/2015] [Accepted: 02/10/2015] [Indexed: 12/29/2022] Open
Abstract
As the number of people diagnosed with Alzheimer's disease (AD) reaches epidemic proportions, there is an urgent need to develop effective treatment strategies to tackle the social and economic costs of this fatal condition. Dozens of candidate therapeutics are currently being tested in clinical trials, and compounds targeting the aberrant accumulation of tau proteins into neurofibrillary tangles (NFTs) are the focus of substantial current interest. Reliable, translatable biomarkers sensitive to both tau pathology and its modulation by treatment along with animal models that faithfully reflect aspects of the human disease are urgently required. Magnetic resonance imaging (MRI) is well established as a valuable tool for monitoring the structural brain changes that accompany AD progression. However the descent into dementia is not defined by macroscopic brain matter loss alone: non-invasive imaging measurements sensitive to protein accumulation, white matter integrity and cerebral haemodynamics probe distinct aspects of AD pathophysiology and may serve as superior biomarkers for assessing drug efficacy. Here we employ a multi-parametric array of five translatable MRI techniques to characterise the in vivo pathophysiological phenotype of the rTg4510 mouse model of tauopathy (structural imaging, diffusion tensor imaging (DTI), arterial spin labelling (ASL), chemical exchange saturation transfer (CEST) and glucose CEST). Tau-induced pathological changes included grey matter atrophy, increased radial diffusivity in the white matter, decreased amide proton transfer and hyperperfusion. We demonstrate that the above markers unambiguously discriminate between the transgenic group and age-matched controls and provide a comprehensive profile of the multifaceted neuropathological processes underlying the rTg4510 model. Furthermore, we show that ASL and DTI techniques offer heightened sensitivity to processes believed to precede detectable structural changes and, as such, provides a platform for the study of disease mechanisms and therapeutic intervention.
Collapse
Affiliation(s)
- J A Wells
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
| | - J M O'Callaghan
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - H E Holmes
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - N M Powell
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK; Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK
| | - R A Johnson
- Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
| | - B Siow
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - F Torrealdea
- Brain Repair & Rehabilitation, Institute of Neurology, University College London, UK
| | - O Ismail
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - S Walker-Samuel
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - X Golay
- Brain Repair & Rehabilitation, Institute of Neurology, University College London, UK
| | - M Rega
- Brain Repair & Rehabilitation, Institute of Neurology, University College London, UK
| | - S Richardson
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - M Modat
- Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK
| | - M J Cardoso
- Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK
| | - S Ourselin
- Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK
| | - A J Schwarz
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
| | - Z Ahmed
- Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
| | - T K Murray
- Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
| | - M J O'Neill
- Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
| | - E C Collins
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
| | - N Colgan
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| | - M F Lythgoe
- UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK
| |
Collapse
|
30
|
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-879. [PMID: 25725046 DOI: 10.1093/annonc/mdv106] [Citation(s) in RCA: 116] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 02/16/2015] [Indexed: 02/11/2024] Open
Abstract
BACKGROUND Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for randomized cancer clinical trials (RCTs) in breast cancer. PATIENTS AND METHODS A literature review was carried out to identify TTE end points (primary or secondary) reported in publications of randomized trials or guidelines. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points based on a validated consensus method that formalize the degree of agreement among experts. RESULTS Recommended guidelines for the definitions of TTE end points commonly used in RCTs for breast cancer are provided for non-metastatic and metastatic settings. CONCLUSION The use of standardized definitions should facilitate comparisons of trial results and improve the quality of trial design and reporting. These guidelines could be of particular interest to those involved in the design, conducting, reporting, or assessment of RCT.
Collapse
Affiliation(s)
- S Gourgou-Bourgade
- Biostatistic Unit, Montpellier Cancer Institute, Montpellier; Data Center for Cancer Clinical Trials, CTD-INCa, Montpellier, France.
| | - D Cameron
- Edinburgh Cancer Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK
| | - P Poortmans
- Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands
| | - B Asselain
- Department of Biostatistics, Institut Curie, Paris
| | - D Azria
- Department of Radiation Oncology, Montpellier Cancer Institute, Montpellier, France
| | - F Cardoso
- Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - R A'Hern
- Institute of Cancer Research, London, UK
| | - J Bliss
- Institute of Cancer Research, London, UK
| | - J Bogaerts
- EORTC Data Center (European Organization of Research and Treatment of Cancer - Statistics Department), Brussels, Belgium
| | - H Bonnefoi
- Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - E Brain
- Departments of Clinical Research and Medical Oncology, Institut Curie - Hôpital René Huguenin, Saint-Cloud
| | - M J Cardoso
- Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - B Chibaudel
- Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France
| | - R Coleman
- FRCP, FRCPE YCR National Institute for Health Research Cancer Research Network (NCRN), Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Cancer Research Centre, Sheffield, UK
| | - T Cufer
- University Clinic Golnik, Golnik, Slovenia
| | - L Dal Lago
- Institut Jules Bordet, University 'Libre' of Brussels, Brussels, Belgium
| | - F Dalenc
- Institut Claudius Régaud, Toulouse
| | - E De Azambuja
- Institut Jules Bordet, University 'Libre' of Brussels, Brussels, Belgium
| | - M Debled
- Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - S Delaloge
- Breast Cancer Group, Gustave Roussy Institute, Villejuif
| | | | - J Gligorov
- APHP Tenon - University Cancer Institute - Pierre & Marie Curie, Sorbonne University, Paris
| | | | - W Jacot
- Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France
| | - C Kirkove
- Université catholique Louvain, Louvain-la-Neuve, Belgium
| | - G MacGrogan
- Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - S Michiels
- Biostatistic and Epidemiology Unit, Gustave Roussy, Villejuif; University of Paris-Sud, Villejuif, France
| | - I Negreiros
- Breast Unit, Hospital CUF Descobertas, Lisbon, Portugal
| | - B V Offersen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - F Penault Llorca
- Centre Jean Perrin, Clermont-Ferrand; ERTICA EA4677, UFR Medicine, University of Clermont-Ferrand 1, Clermont-Ferrand, France
| | - G Pruneri
- European Institute of Oncology, Milan; University of Milan, School of Medicine, Milan, Italy
| | - H Roche
- Institut Claudius Régaud, Toulouse
| | - N S Russell
- Department of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwnhoek Hospital, Amsterdam, The Netherlands
| | - F Schmitt
- IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Porto; Medical Faculty of Porto University, Porto, Portugal
| | - V Servent
- Oscar Lambret Comprehensive Cancer Center, Lille, France
| | - B Thürlimann
- Kantonsspital St Gallen, Breast Center, St Gallen, Switzerland
| | - M Untch
- Clinic for Gynecology, Gynecologic Oncology and Obstetrics-Interdisciplinary Breast Cancer Center, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - J A van der Hage
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam
| | - G van Tienhoven
- Academic Medical Center Amsterdam, Amsterdam, The Netherlands
| | - H Wildiers
- Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven; Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, Leuven, Belgium
| | - J Yarnold
- The Institute of Cancer Research, Royal Cancer Hospital, London, UK
| | - F Bonnetain
- Methodological and Quality of Life Unit in Oncology (EA3181), CHU Besançon, Besançon
| | - S Mathoulin-Pélissier
- Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux
| | - C Bellera
- Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux
| | - T S Dabakuyo-Yonli
- Biostatistics and Quality of Life Unit (EA4184), Centre Georges François Leclerc Comprehensive Cancer Centre, Dijon, France
| |
Collapse
|
31
|
Menezes CB, Ticona-Benavente CA, Tardin FD, Cardoso MJ, Bastos EA, Nogueira DW, Portugal AF, Santos CV, Schaffert RE. Selection indices to identify drought-tolerant grain sorghum cultivars. Genet Mol Res 2014; 13:9817-27. [PMID: 25501191 DOI: 10.4238/2014.november.27.9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Twenty-five cultivars of grain sorghum [Sorghum bicolor (L.) Moench] were examined under both drought stress and normal conditions in 4 experiments. In each condition, genotypes were evaluated in a factorial experiment using a randomized complete block design with 3 replications. Eight drought tolerance indices including stability tolerance index, mean productivity (MP), geometric MP, harmonic mean, stress susceptibility index, tolerance index, yield index, and yield stability index were estimated for each genotype based on grain yield under drought (Ys) and irrigated conditions (Yp). The results indicated that there were positive and significant correlations among Yp and Ys with geometric MP, MP, harmonic mean, and stability tolerance index, indicating that these factors are better predictors of Yp and Ys than tolerance index, stress susceptibility index, yield stability index, and yield index. Based on adjusted means at Yp and Ys, indices geometric MP, MP, harmonic mean, and stability tolerance index, unweighted pair group method with arithmetic mean cluster and biplot analysis, the most tolerant cultivars were '9929020', '9929034', and 'N 95B'.
Collapse
Affiliation(s)
- C B Menezes
- Embrapa Milho e Sorgo, Sete Lagoas, MG, Brasil
| | | | - F D Tardin
- Embrapa Milho e Sorgo, Sete Lagoas, MG, Brasil
| | | | - E A Bastos
- Embrapa Meio Norte, Teresina, PI, Brasil
| | - D W Nogueira
- Universidade Federal de Lavras, Lavras, MG, Brasil
| | | | - C V Santos
- Universidade Federal de São João Del-Rei, Sete Lagoas, MG, Brasil
| | | |
Collapse
|
32
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014; 25:1871-1888. [PMID: 25234545 PMCID: PMC4176456 DOI: 10.1093/annonc/mdu385] [Citation(s) in RCA: 284] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/11/2014] [Indexed: 12/23/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, Denmark
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
33
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23:489-502. [PMID: 25244983 DOI: 10.1016/j.breast.2014.08.009] [Citation(s) in RCA: 194] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/12/2014] [Indexed: 12/25/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, Arome, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, DE, USA
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | | |
Collapse
|
34
|
Almeida Filho JE, Tardin FD, Daher RF, Barbé TC, Paula CM, Cardoso MJ, Godinho VPC. Stability and adaptability of grain sorghum hybrids in the off-season. Genet Mol Res 2014; 13:7626-35. [PMID: 24737511 DOI: 10.4238/2014.march.24.24] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We analyzed productivity data obtained from experiments on grain sorghum conducted in 7 locations of its cultivation in Brazil. A total of 25 hybrids were analyzed, of which 22 were pre-commercial and 3 were cultivars. The Wricke and Purchase et al. methods were highly consistent in identifying individuals with low contributions to genotype x environment interactions. The Lin and Binns method proved to be easily applicable and interpretable but it was not efficient in detecting individuals with specific adaptations. An additive main effect and multiplicative interaction (AMMI) model indicated the suitability of cultivar 1G282 for the cities of Guaíra, Sete Lagoas, and Vilhena, and hybrids 0307087 and 0307091 for the southeast of Goiás. The associations of the Eberhart and Russell method with AMMI indicated that 0307071, 0307131, 0307511, and 0307651 showed adaptability to favorable environments. Hybrid 0009061 stood out as the most adaptable and stable cultivar.
Collapse
Affiliation(s)
- J E Almeida Filho
- Laboratório de Engenharia Agrícola, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, Brasil
| | - F D Tardin
- Núcleo de Recursos Genéticos e Obtenção de Cultivares, Embrapa Milho e Sorgo, Sete Lagoas, MG, Brasil
| | - R F Daher
- Laboratório de Engenharia Agrícola, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, Brasil
| | - T C Barbé
- Laboratório de Engenharia Agrícola, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, Brasil
| | - C M Paula
- Departamento Comercial, Cereal Ouro, Rio Verde, GO, Brasil
| | - M J Cardoso
- Setor de Produção Vegetal, Grupo de Pesquisa e Desenvolvimento, Embrapa Meio Norte, Teresina, Piauí, Brasil
| | - V P C Godinho
- Núcleo de Produção Vegetal, Embrapa Rondônia, Vilhena, RO, Brasil
| |
Collapse
|
35
|
Immink JM, Putter H, Bartelink H, Cardoso JS, Cardoso MJ, van der Hulst-Vijgen MHV, Noordijk EM, Poortmans PM, Rodenhuis CC, Struikmans H. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial. Ann Oncol 2012; 23:2591-2598. [PMID: 22499858 DOI: 10.1093/annonc/mds066] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND In breast cancer treated with breast-conserving radiotherapy, the influence of the boost dose on cosmetic outcome after long-term follow-up is unknown. PATIENTS AND METHODS We included 348 patients participating in the EORTC 'boost versus no boost' mega trial with a minimum follow-up of 6 years. Digitalised pictures were analysed using specific software, enabling quantification of seven relative asymmetry features associated with different aspects of fibrosis. RESULTS After 3 years, we noted a statistically significantly poorer outcome for the boost patients for six features compared with those of the no boost patients. Up to 9 years of follow-up, results continued to worsen in the same magnitude for the both patient groups. We noted the following determinants for poorer outcome: (i) boost treatment, (ii) larger excision volumes, (iii) younger age, (iv) tumours located in the central lower quadrants of the breast and (v) a boost dose administered with photons. CONCLUSIONS A boost dose worsens the change in breast appearance in the first 3 years. Moreover, the development of fibrosis associated with whole-breast irradiation, as estimated with the relative asymmetry features, is an ongoing process until (at least) 9 years after irradiation.
Collapse
Affiliation(s)
- J M Immink
- Department of Radiotherapy, Medical Center, Reinier de Graaf Groep, Delft.
| | - H Putter
- Department of Statistics, Leiden University Medical Center, Leiden
| | - H Bartelink
- Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - J S Cardoso
- Electrical and Computer Engineering INESC Porto, Faculty of Engineering, University of Porto, Porto
| | - M J Cardoso
- Department of Surgery, Champalimaud Cancer Center, Lisbon, Portugal
| | | | - E M Noordijk
- Department of Radiotherapy, Leiden University Medical Center, Leiden
| | - P M Poortmans
- Department of Radiation Oncology, Institute Verbeeten, Tilburg
| | - C C Rodenhuis
- Department of Radiotherapy, University Medical Center Utrecht, Utrecht
| | - H Struikmans
- Department of Radiotherapy, Leiden University Medical Center, Leiden; Department of Radiotherapy, Radiotherapy Centre West, The Hague, The Netherlands
| |
Collapse
|
36
|
Torres Costa J, Sá R, Cardoso MJ, Silva R, Ferreira J, Ribeiro C, Miranda M, Plácido JL, Nienhaus A. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay. Eur Respir J 2010; 34:1423-8. [PMID: 19948911 DOI: 10.1183/09031936.00053809] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The prevalence of latent tuberculosis (TB) infection (LTBI) and the incidence of active tuberculosis in healthcare workers (HCWs) in a Portuguese hospital were examined. This cross-sectional study comprises 4,735 hospital workers screened between May 2005 and September 2008. Tuberculin skin test (TST) and interferon-gamma release assay (IGRA) were used simultaneously in 1,219 HCWs (25.7%). Radiographs were taken in symptomatic HCWs or in test-positive HCWs. The tests were repeated annually or bi-annually depending on risk assessment. IGRA was positive in 32.6% and TST in 74.2% of the HCWs. Years spent in healthcare were a risk factor for a positive IGRA, but not for a positive TST. Repeated bacillus Calmette-Guérin vaccination increased the probability of TST+/IGRA- discordance (35.4% versus 54.4%, respectively). In those tested three times with TST during the study period (n = 59), the mean diameter of TST increased from 5 to 7 to 10 mm. Within 3 yrs, 31 HCWs were diagnosed with active TB (annual incidence rate 191 out of 100,000 people). In eight HCWs with active TB, TST and IGRA were performed at the time of diagnosis and each test was positive. TB burden in HCWs in Portugal is high. With IGRA, the number of radiographs needed to exclude active TB could have been reduced by about half without missing a case of active TB. Therefore IGRA should be introduced into TB screening programmes.
Collapse
Affiliation(s)
- J Torres Costa
- Occupational Health Division, Alameda Professor Hernâni Monteiro, Hospital S. João, Porto, Portugal
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Ramos MI, Cardoso MJ, Vaz F, Torres MD, García F, Blanco G, González EM. [Influence of the grade of anxiety and level of cortisol on post-surgical recovery]. Actas Esp Psiquiatr 2008; 36:133-137. [PMID: 18478452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
INTRODUCTION The objective is to analyze the influence of several biological and/or psychological factors on postsurgery recovery. METHOD Our sample was made up of 42 inpatients waiting for surgery. The day before the intervention, they filled out Spielbergers' State/Trait Anxiety Inventory (STAI) and sample of saliva was collected at 8:00 in order to determine cortisol concentration. Recovery was codified as <<good>> or <<poor>> using the Moix criteria (1995). RESULTS Patients with higher scores on the STAI had higher levels of salivary cortisol and their recovery was worse compared with patients with low anxiety. CONCLUSIONS Our results confirm the relationship between specific psychological variables, cortisol levels and the characteristics of the surgery recovery process of the patients.
Collapse
Affiliation(s)
- M I Ramos
- Departamento de Farmacología y Psiquiatría, Universidad de Extremadura Badajoz
| | | | | | | | | | | | | |
Collapse
|
38
|
Fitzal F, Krois W, Trischler H, Wutzel L, Riedl O, Kühbelböck U, Wintersteiner B, Cardoso MJ, Dubsky P, Gnant M, Jakesz R, Wild T. The use of a breast symmetry index for objective evaluation of breast cosmesis. Breast 2007; 16:429-35. [PMID: 17382546 DOI: 10.1016/j.breast.2007.01.013] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2006] [Revised: 01/28/2007] [Accepted: 01/31/2007] [Indexed: 11/25/2022] Open
Abstract
The cosmetic result after breast surgery is an important marker in clinical studies. Most authors used subjective scales to judge breast cosmesis. However, inter-observer discrepancies are very high and the use of such subjective scales for prospective trials is highly disputed. In this study we present for the first time a new invented breast symmetry index (BSI). This BSI is calculated by subtracting the size and the shape between both breasts (frontal view and side view). The BSI is measured with a software system called breast analysing tool (BAT) from digital photographs. The photographs of 27 patients have been analysed with this software by different physicians to evolve inter-observer reproducibility. The Harris scale for subjective cosmetic analyses has been correlated with the BSI. In our study the inter-observer reproducibility was excellent (Pearson correlation r=0.9; p<0.05) and the BSI was able to significantly differentiate between good and bad cosmesis (BSI values from 0%d to 30%d is good, BSI>30%d is bad cosmesis). Thus the BSI may be used for clinical studies.
Collapse
Affiliation(s)
- F Fitzal
- Department of Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
João Silva M, Ferraz C, Pissarra S, Cardoso MJ, Simões J, Bonito Vítor A. Role of viruses and atypical bacteria in asthma exacerbations among children in Oporto (Portugal). Allergol Immunopathol (Madr) 2007; 35:4-9. [PMID: 17338895 DOI: 10.1157/13099088] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
BACKGROUND Upper respiratory tract infections are known to be a significant precipitant of acute asthma exacerbations. The aim of this study was to evaluate seasonal trends and the role of these pathogens in asthma exacerbations in school-aged children from Oporto (Portugal). METHODS Nasal aspirates were collected from children aged 6 to 12 years old with asthma exacerbations attended in the Pediatric Emergency Department one day per week from January 1 to December 31, 2003. Demographic data, severity of asthma and asthma exacerbations, and current treatment were recorded. Samples were obtained through nasal wash with 1 ml saline and were processed by immunofluorescence assays (respiratory syncytial virus, adenovirus, parainfluenza and influenza virus), retrotranscription polymerase chain reaction (rhinovirus) and polymerase chain reaction (enterovirus, Chlamydia pneumoniae and Mycoplasma pneumoniae). RESULTS In 54 eligible children, 37 nasal samples were obtained. Infectious agents were detected in 78 % of the patients. Rhinovirus was detected in 70.3 %, Mycoplasma pneumoniae in 16.2 %, enterovirus in 10.8 %, and Chlamydia pneumoniae in 2.7 %. Coinfection was identified in 21.6 % of the samples. There was no significant correlation between current treatment status, severity of asthma or exacerbations and the isolated agents. Two distinct peaks of asthma exacerbation were found, 40.5 % in spring and 32.4 % in autumn [corrected] The highest number of cases was recorded in March and the lowest in August and January. Rhinoviruses was detected in 27 % of the cases in autumn and in 24.3 % in spring [corrected] CONCLUSIONS These results confirm the previously reported high frequency of rhinovirus detection in asthma exacerbations in children and provide evidence that asthma exacerbations and rhinovirus infections follow a seasonal pattern, occurring mostly in spring and autumn. The findings also underscore the frequency of Mycoplasma pneumoniae detection, and emphasize the importance of this agent as a possible trigger of asthma exacerbations.
Collapse
Affiliation(s)
- M João Silva
- Department of Pediatrics, Hospital de São João, Oporto, Portugal.
| | | | | | | | | | | |
Collapse
|
40
|
Abstract
The preparation of a particular motor pattern is related to the information available that enables the actor to predict the correct response to a forthcoming stimulus. In many situations, however, prediction is not possible. In such cases, the individual can guess the probable parameters of the next stimulus. The authors attempted to establish the bias in the motor intention for movement and its interaction with a possible memory trace of the stimulus-response mapping produced by the preceding stimulus. Two letters were presented bilaterally, and participants (N=21) had to discriminate the target letter and respond with the compatible hand. The present findings support the existence of a memory trace of the previous stimulus-response mapping.
Collapse
Affiliation(s)
- C M Gómez
- Dpto. Psicología Experimental, Facultad de Psicología, Universidad de Sevilla, C/ Camilo José Cela s/n, Sevilla 41018. Spain.
| | | | | | | | | |
Collapse
|
41
|
Abstract
The aim of present work is to test possible gender differences in the ERPs to the standards during the performance of a visual-spatial attention task. The sample: 20 subjects (10 women) aged 18-24. Electrodes: F3, F4, C3, C4, P3, P4, T5, T6, O1, O2. ANOVA tests were computed with the following factors: attention, gender, visual field, hemisphere, and electrodes. Results showed that men presented higher amplitudes in P1 and in P3b than did women, and women presented higher amplitudes in the temporal N1 than did men. For the P3, the amplitude in frontal-central regions for the attended condition was higher in men than in women, and men presented a gender-specific right frontal functional asymmetry that was not present in women. Since these components are related with the modulation of visual processing by the effect of spatial attention, the intra- and inter-gender differences obtained suggest possible differences in the processing of visual information in both genders. However, the fact that the brain generators could have a different orientation is also a possible explanation for the differences obtained in the ERPs in both genders.
Collapse
Affiliation(s)
- E Vaquero
- University de Sevilla, Department of Experimental Psychobiology, Laboratory of Physiology, Sevilla, Spain
| | | | | | | |
Collapse
|
42
|
Vázquez Marrufo M, Vaquero E, Cardoso MJ, Gómez CM. Temporal evolution of alpha and beta bands during visual spatial attention. Brain Res Cogn Brain Res 2001; 12:315-20. [PMID: 11587900 DOI: 10.1016/s0926-6410(01)00025-8] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Event-related potentials (ERPs) are an electrophysiological index of various cognitive processes such as attention. However, this kind of analysis does not allow observation of differences in the spectral content taking place during a sensory, cognitive or motor task. The goal of the present work was to compute the temporal dynamics of EEG oscillations using a technique called temporal spectral evolution (TSE). The electroencephalogram (EEG) was recorded during the presentation of flashed stimuli that were randomly presented to the left or right visual field. Subjects were asked to pay attention, alternately in different blocks of trials, to the left or to the right to detect an infrequent target. The results showed a decrease in the alpha band in a time window of 375-500 ms and an increase in the beta band at 500-875 ms after stimulus onset, for both attended and unattended stimuli. Statistical analysis showed that the decrease in alpha and the increase in beta were more marked during the attentional condition. In conclusion, these results demonstrate that the decrease in alpha band and the increase in beta band are electrophysiological markers of visual spatial attention.
Collapse
Affiliation(s)
- M Vázquez Marrufo
- Laboratorio Psicobiología, Departamento Psicología Experimental, Facultad de Psicología, Avenida San Francisco Javier s/n, 41005, Sevilla, Spain.
| | | | | | | |
Collapse
|
43
|
Vázquez M, Vaquero E, Cardoso MJ, Gómez CM. [Temporal spectral evolution of electroencephalogram. Methodology and applications]. Rev Neurol 2001; 33:525-30. [PMID: 11727232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
INTRODUCTION The event related potentials (ERPs) allow to study the evolution of the cerebral electric activity related with the diverse sensorial, motors and cognitive processes. However, the ERPs and the spectral analyses based in Fast Fourier Transform, are not able to show the variations along the time of the spectral content of the electroencephalogram (EEG). OBJECTIVE The present work will show the necessary methodology to obtain the temporal dynamics of the frequency (TSE) in the EEG, a technique described by Salmelin and Hari (1994) that allows the analysis of the modulations of any spectral band along the time. SUBJECTS AND METHODS The presented data correspond to the electroencephalographic registration of 20 human subjects during an experiment of visual spatial attention. RESULTS The modulations of the ERPs differ of the observed by the spectral techniques in latency and topography. Likewise, comparing different spectral techniques is proven that the TSE allows to define with more temporal precision the variations on the spectral content. CONCLUSION The application of the TSE technique to the same EEG signal that is used for obtaining the ERPs, allows the inclusion of the variable time in the spectral analysis of the EEG, what can be crucial to understand the physiological bases of some neuropathologies.
Collapse
Affiliation(s)
- M Vázquez
- Laboratorio de Psicobiología, Departamento de Psicología Experimental, Facultad de Psicología de la Universidad de Sevilla, Sevilla, 41005, España.
| | | | | | | |
Collapse
|
44
|
Gómez CM, Delinte A, Vaquero E, Cardoso MJ, Vázquez M, Crommelinck M, Roucoux A. Current source density analysis of CNV during temporal gap paradigm. Brain Topogr 2001; 13:149-59. [PMID: 11302395 DOI: 10.1023/a:1007816201345] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The present report studied the contingent negative variation during Gap and Non-Gap conditions using visual stimulation and manual responses. The reaction times during the Gap condition were facilitated compared with those of the Non-Gap condition. The contingent negative variation component was obtained during the preparatory period from electrodes placed at 58 scalp sites for both Gap and Non-Gap conditions. The comparison between both conditions: Gap and non-gap did not show statistically significant differences during the preparatory period. The topography of the voltage and current source density maps showed three different foci: (i) an early negativity centred in electrodes overlying the supplementary motor area and cingulate motor areas, (ii) an activation over the primary motor cortex contralateral to the finger movement, and (iii) a bilateral activation on posterior sites. All these results suggest that the facilitation induced by the warning stimuli occurs in neural circuits that would be recruited for the subsequent processing of the imperative stimulus. The facilitation of the reaction times during the gap condition with respect to non-gap condition must be justified by neural events occurring during the gap period.
Collapse
Affiliation(s)
- C M Gómez
- Lab. Psicobiología. Dpto. Psicología Experimental, Universidad de Sevilla, Spain.
| | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
In this study, we recorded the event-related potentials (ERPs) elicited by stimuli appearing at attended and unattended locations. The voltage amplitudes and latencies of the P1, N1, P2, N2 and P3 visual components showed statistically significant differences in the attended condition with respect to the unattended one. The power spectral density of the EEG following stimulus onset was calculated. The difference between the spectral densities of the attended and unattended conditions was computed. Statistically significant differences were found in the decrease of alpha (9-11 Hz) and the increase of beta (15-17 Hz) frequencies during the attention condition with respect to the unattended condition. These results suggest that the arrival of a visual stimulus during the attended condition generates a complex reorganization of neuronal activity in both time and frequency domains.
Collapse
Affiliation(s)
- C M Gómez
- Dept. de Psicología Experimental, Universidad de Sevilla, Spain
| | | | | | | | | |
Collapse
|
46
|
Ayres de Campos D, Cardoso MJ, Martinez de Oliveira J. [Hormone replacement therapy and cancer of the breast. 2. Should a woman with cancer of the breast receive hormone replacement therapy?]. ACTA MEDICA PORT 1997; 10:705-11. [PMID: 9477596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The common menopausal symptoms of a growing number of women treated for breast cancer poses difficult therapeutic decisions to the Gynaecologist. It has been extensively demonstrated that hormonal replacement therapy (HRT) is the most effective treatment of such symptoms, as well as protecting women from cardiovascular disease, osteoporosis and increased mortality related to these disorders. However, breast cancer is classically considered a contraindication to HRT. In this paper we review the existing evidence regarding the influence of HRT on breast cancer. A computerized bibliographical search (MEDLINE) of literature in the English-language literature published in the last 15 years was conducted, followed by a hand search of references found in these papers. Evidence on the response of breast cancer cells to HRT is derived from animal studies, tissue growth system experiments, indirect epidemiological data and clinical data. While the bulk of experimental evidence points towards a proliferative effect of estrogen on breast cancer cells, almost all clinical reports have found no adverse effects of HRT on these patients. In our opinion, currently existing evidence does not justify the denial of HRT to breast cancer patients whose quality of life is at stake. Such is the case of women with intense menopausal symptoms unresponsive to alternative therapies. This opinion is shared by numerous other authors and a small number of eminent institutions. We believe it is safer to avoid HRT, in asymptomatic women as long-term regimens would be needed for protection against cardiovascular disease and osteoporosis, and the risks of such regimens have yet to be evaluated. We also believe that large randomized trials are now ethically justified and greatly needed to obtain safer data on this subject.
Collapse
Affiliation(s)
- D Ayres de Campos
- Departamento de Ginecologia e Obstetrícia, Hospital de São João, Faculdade de Medicina do Porto
| | | | | |
Collapse
|
47
|
Pinto-Ribeiro J, Magalhães JA, Cardoso MJ, Paula-Barbosa MM, Sobrinho-Simões MA. Asymmetric bilateral megalencephaly. A case report. ACTA MEDICA PORT 1983; 4:497-500. [PMID: 6666685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|